Both, in vitro and in vivo, we roundly validated that CCL2 was upregulated in TMZ-treated GBM cells, and ADAM8 knockdown reduced CCL2 expression in GBM cells under TMZ treatment. The gene discussed is ADAM8; the disease is glioblastoma.